Biorepository and clinical research laboratories in Pakistan operate in a long-horizon stewardship model, where responsibility for a sample extends far beyond collection and initial testing. While SOPs describe controlled workflows, real-world operations are shaped by multi-year studies, overlapping protocols, storage constraints, and evolving ethical requirements. This reality check explains how biorepositories actually function day to day.
As repositories grow, early-stage documentation gaps propagate downstream, making long-term traceability difficult.
Aliquoting is one of the highest-risk stages for traceability loss.
Over time, location drift becomes a significant operational risk.
This creates ethical and audit exposure.
Reconstructing a full sample history years later is time-consuming and uncertain.
Pharma LIMS implementation requires validation, training, and ongoing governance.
Implementing without validation planning compromises regulatory acceptance.
Partial or non-validated systems that increase regulatory risk.
Biorepositories in Pakistan function through manual diligence rather than enforced governance. As sample counts, study overlap, and storage duration increase, this operating model becomes fragile. Understanding this reality is essential before analyzing failure points and regulatory expectations.